Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer
dc.contributor.author | Alhussan, Abdulaziz | |
dc.contributor.author | Jackson, Nolan | |
dc.contributor.author | Eaton, Sarah | |
dc.contributor.author | Dos Santos, Nancy | |
dc.contributor.author | Barta, Ingrid | |
dc.contributor.author | Zaifman, Josh | |
dc.contributor.author | Chen, Sam | |
dc.contributor.author | Tam, Yuen Y.C. | |
dc.contributor.author | Krishnan, Sunil | |
dc.contributor.author | Chithrani, Devika B. | |
dc.date.accessioned | 2023-10-15T13:53:46Z | |
dc.date.available | 2023-10-15T13:53:46Z | |
dc.date.copyright | 2022 | en_US |
dc.date.issued | 2022 | |
dc.description.abstract | Current chemoradiation therapy suffers from normal tissue toxicity. Thus, we are proposing incorporating gold nanoparticles (GNPs) and docetaxel (DTX), as they have shown very promising synergetic radiosensitization effects. Here, we explored the effect of a DTX prodrug encapsulated in lipid nanoparticles (LNPDTX-P) on GNP uptake in pancreatic cancer models in vitro and in vivo. For the in vitro experiment, a pancreatic cancer cell line, MIA PaCa-2, was cultured and dosed with 1 nM GNPs and 45 nM free DTX or an equivalent dose of LNPDTX-P. For the in vivo experiment, MIA PaCa-2 cells were implanted subcutaneously in NRG mice, and the mice were dosed with 2 mg/kg of GNPs and 6 mg/kg of DTX or an equivalent dose of LNPDTX-P. The results show that LNPDTX-P-treated tumour samples had double the amount GNPs compared to control samples, both in vitro and in vivo. The results are very promising, as LNPDTX-P have superior targeting of tumour tissues compared to free DTX due to their nanosize and their ability to be functionalized. Because of their minimal toxicity to normal tissues, both GNPs and LNPDTX-P could be ideal radiosensitization candidates in radiotherapy and would produce very promising synergistic therapeutic outcomes. | en_US |
dc.description.reviewstatus | Reviewed | en_US |
dc.description.scholarlevel | Faculty | en_US |
dc.description.sponsorship | This study was funded by the Kuwait Foundation for the Advancement of Sciences (KFAS) under project code CB21-63SP-01; the Nanomedicines Innovation Network Strategic Initiative fund (NMIN-SI); the John R. Evans Leaders Fund (JELF) from the Canada Foundation for Innovation (CFI) and the British Columbia Knowledge Development Fund (BCKDF); an NSERC Discovery grant from the Natural Sciences and Engineering Research Council of Canada (NSERC); grants R01CA257241, R01DE028105, R21CA252156, and R01CA274415 from the National Institutes of Health (NIH) of United States of America; and a collaborative health grant from the University of Victoria. | en_US |
dc.identifier.citation | Alhussan, A., Jackson, N., Eaton, S., Santos, N. D., Barta, I., Zaifman, J., Chen, S., Tam, Y. K., Krishnan, S., & Chithrani, D. B. (2022). Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer. Cancers, 14(24), 6137. https://doi.org/10.3390/cancers14246137 | en_US |
dc.identifier.uri | https://doi.org/10.3390/cancers14246137 | |
dc.identifier.uri | http://hdl.handle.net/1828/15528 | |
dc.language.iso | en | en_US |
dc.publisher | Cancers | en_US |
dc.subject | gold nanoparticles | en_US |
dc.subject | docetaxel | en_US |
dc.subject | lipid nanoparticles | en_US |
dc.subject | pancreatic cancer | en_US |
dc.subject | nanomedicine | en_US |
dc.title | Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- alhussan_abdulazziz_cancers_2022_FINAL.pdf
- Size:
- 1.49 MB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 2 KB
- Format:
- Item-specific license agreed upon to submission
- Description: